What to Make of the GLP-1 Coverage and Cost Landscape
How payers are handling the rise of GLP-1s? Cost and clinical transparency can support whatever strategy a plan takes.
How payers are handling the rise of GLP-1s? Cost and clinical transparency can support whatever strategy a plan takes.
RxSS member support comes from pharmacy technicians who go all out to find affordable prescriptions and deliver peace of mind.
Consumers have more choices for purchasing prescriptions without insurance. How can plans capture what they’re missing?
Up to 10 competing products for Humira are on the way in 2023. What should health plans and plan sponsors be following as the biosimilars landscape takes shape?
Some lesser-known facts about this chronic condition underscore the importance of medication adherence, and the positive impact RxSS can have on members with diabetes.
The Inflation Reduction Act has the potential to lower prescription drug costs for millions of Americans and raise them for millions more. Who stands to gain or lose?
We know many members are scrambling to find pharmacies with the common ADHD medication in stock. With this and other drug shortages, RxSS can be an invaluable resource.
A wave of FDA-approved biosimilars for Humira and other costly biologics will enter the U.S. market in 2023. What does it mean for patients, payers and plan designs?
Members shouldn’t confuse our clinical suggestions for intervention. Medication decisions are between patient and doctor. RxSS informs those discussions, and makes it easy to make a change.
Free PBM tools can help members get more from their pharmacy benefits, maybe even save on certain prescriptions. What more can you ask for? Quite a bit, actually.